NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Brain Tumor
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Malignant Germ Cell Tumor
Recurrent Childhood Medulloblastoma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Childhood Soft Tissue Sarcoma
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor

Interventions: Drug: erlotinib hydrochloride
Drug: temozolomide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-02-12

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT00077454

Locations: 🇺🇸
COG Phase I Consortium, Arcadia, California, United States

Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: bortezomib
Other: laboratory biomarker analysis

First Posted Date: 2004-02-12

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00077441

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: tipifarnib
Drug: capecitabine

First Posted Date: 2004-02-12

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00077363

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer

Interventions: Drug: triapine
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2004-02-12

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00077350

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor
Sarcoma

Interventions: Drug: semaxanib

First Posted Date: 2004-02-12

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00005862

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: romidepsin

First Posted Date: 2004-02-11

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00077194

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Howard University Cancer Center at Howard University Hospital, Washington, District of Columbia, United States

and more 1 locations

Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Stage IVB Rectal Cancer
Recurrent Rectal Cancer
Recurrent Colon Cancer
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer

Interventions: Biological: cetuximab
Biological: bevacizumab
Drug: irinotecan hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2004-02-11

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00077298

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Blastic Phase Chronic Myelogenous Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Relapsing Chronic Myelogenous Leukemia

Interventions: Drug: cytarabine
Drug: triapine
Other: laboratory biomarker analysis

First Posted Date: 2004-02-11

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00077181

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: cilengitide

First Posted Date: 2004-02-11

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00077155

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: dendritic cell-MART-1 peptide vaccine
Biological: gp100 antigen
Biological: therapeutic tumor infiltrating lymphocytes
Biological: tyrosinase peptide

First Posted Date: 2004-02-09

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003665

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

Home Terms & Conditions Privacy Policy